Lung Cancer in Finland
- PMID: 39242140
- DOI: 10.1016/j.jtho.2024.06.005
Lung Cancer in Finland
Conflict of interest statement
Disclosure Dr. Andersén reports funding by the state subsidy of Turku University Hospital, travel costs by Cancer Society of Finland and Pfizer, and steering committee membership for Nordic Thoracic Oncology Group. Dr. Aro reports support attending meeting for AstraZeneca and Orion, and eLive Ecosystems stock ownership. Dr. Kaarteenaho reports grants by the Tampere Tuberculosis Foundation, the state subsidy of Oulu University Hospital, consulting fees by Boehringer-Ingelheim, Merck Sharp & Dohme and payment for lecture by Boehringer-Ingelheim, virtual meeting support by Novartis, membership of the board of the Finnish Medical Foundation from January 2020 to December 2022, membership of the Finnish Lung Health Association from January 2021 onward, and randomized controlled trial studies, Boehringer-Ingelheim. Dr. Koivunen reports funding from AstraZeneca, Roche, Cancer Foundation Finland, consulting fees from Roche, AstraZeneca, Janssen, Bristol-Myers Squibb, Merck, Amgen, Novartis, Merck KgA, Sanofi, and Pfizer, payment honoraria by Siemens Healthineers, and part-time employment at Faron Pharmaceuticals. Dr. Mäyränpää reports payments or honoraria from Amgen, AstraZeneca, and Bristol-Myers Squibb, payment for expert testimony for Amgen, and participation on an advisory board for Bristol-Myers Squibb. Dr. Sihvo reports consultation fee from Merck Sharp & Dohme, payment or honoraria from AstraZeneca, Merck Sharp & Dohme, and support for travel from Merck Sharp & Dohme. Dr. Vasankari reports consultation fee from Merck Sharp & Dohme and support for attending meetings from Cancer Society Finland.
Similar articles
-
An epidemiological study of lung cancer: history and histological types in a general population in northern Finland.Eur Respir J. 1999 Feb;13(2):436-40. doi: 10.1183/09031936.99.13243699. Eur Respir J. 1999. PMID: 10065694
-
Lung cancer and smoking in Finland and the Czech Republic. Recent trends and predictions.Neoplasma. 1992;39(3):177-84. Neoplasma. 1992. PMID: 1528323
-
On the estimation of lung cancer mortality caused by occupational exposure to environmental tobacco smoke in Finland.J Occup Environ Med. 2004 Feb;46(2):93-5. doi: 10.1097/01.jom.0000113925.88298.5e. J Occup Environ Med. 2004. PMID: 14767211 No abstract available.
-
[Occupational causes of lung cancer].Duodecim. 1998;114(2):125-32. Duodecim. 1998. PMID: 10895478 Review. Finnish. No abstract available.
-
[Gefitinib as targeted treatment for non-small-cell lung cancer].Duodecim. 2005;121(3):267-72. Duodecim. 2005. PMID: 15787284 Review. Finnish. No abstract available.
Cited by
-
A systematic review and meta-analysis of lung cancer risk prediction models.Acta Oncol. 2025 May 12;64:661-671. doi: 10.2340/1651-226X.2025.42529. Acta Oncol. 2025. PMID: 40356086 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical